Cellectar Biosciences Inc CLRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.75
- Day Range
- $2.52–2.76
- 52-Week Range
- $2.43–13.95
- Bid/Ask
- $2.55 / $2.94
- Shares Outstanding
- 7.99M
- Market Cap
- $20.70M
- Volume/Avg
- 183,688 / 982,384
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.cellectar.com
Valuation
|
Metric
|
CLRB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLRB
Financial Strength
|
Metric
|
CLRB
|
|---|---|
Quick Ratio | 1.71 |
Current Ratio | 1.90 |
Interest Coverage | — |
Quick Ratio
CLRB
Profitability
|
Metric
|
CLRB
|
|---|---|
Return on Assets (Normalized) | −140.92% |
Return on Equity (Normalized) | −314.18% |
Return on Invested Capital (Normalized) | −269.56% |
Return on Assets
CLRB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Kdpwpgyf | Kzmxm | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cxspzysk | Tqytmll | $66B | |||
| argenx SE ADR
ARGX
| Zbqvtrv | Szr | $53B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hwwhgzgd | Sshvb | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| Dwpjlrccw | Xhjlvhp | $24B | |||
| BioNTech SE ADR
BNTX
| Ggnrvnqy | Ssp | $23B | |||
| Moderna Inc
MRNA
| Ynzmjjncn | Mks | $20B | |||
| Incyte Corp
INCY
| Qmrghrv | Bgwy | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Jbrrqyjmg | Hzsrz | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Qgxwdxy | Cbxtb | $13B |
United States